Trial · NCT04023526
Adverse events304
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 304
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Thrombocytopenia | Blood and lymphatic system disorders | Cusatuzumab 10 mg/kg Plus Azacitdine | 26 | 51 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Cusatuzumab 20 mg/kg Plus Azacitidine | 30 | 51 | |
| other | Anaemia | Blood and lymphatic system disorders | Cusatuzumab 10 mg/kg Plus Azacitdine | 24 | 51 | |
| other | Anaemia | Blood and lymphatic system disorders | Cusatuzumab 20 mg/kg Plus Azacitidine | 18 | 51 | |
| other | Neutropenia | Blood and lymphatic system disorders | Cusatuzumab 10 mg/kg Plus Azacitdine | 20 | 51 | |
| other | Neutropenia | Blood and lymphatic system disorders | Cusatuzumab 20 mg/kg Plus Azacitidine | 21 | 51 | |
| other | Leukopenia | Blood and lymphatic system disorders | Cusatuzumab 10 mg/kg Plus Azacitdine | 13 | 51 | |
| other | Leukopenia | Blood and lymphatic system disorders | Cusatuzumab 20 mg/kg Plus Azacitidine | 16 | 51 | |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Cusatuzumab 10 mg/kg Plus Azacitdine | 11 | 51 | |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Cusatuzumab 20 mg/kg Plus Azacitidine | 9 | 51 | |
| other | Lymphopenia | Blood and lymphatic system disorders | Cusatuzumab 10 mg/kg Plus Azacitdine | 13 | 51 | |
| other | Lymphopenia | Blood and lymphatic system disorders | Cusatuzumab 20 mg/kg Plus Azacitidine | 7 | 51 | |
| other | Pneumonia | Infections and infestations | Cusatuzumab 10 mg/kg Plus Azacitdine | 15 | 51 | |
| other | Pneumonia | Infections and infestations | Cusatuzumab 20 mg/kg Plus Azacitidine | 13 | 51 | |
| other | COVID-19 pneumonia | Infections and infestations | Cusatuzumab 10 mg/kg Plus Azacitdine | 2 | 51 | |
| other | COVID-19 pneumonia | Infections and infestations | Cusatuzumab 20 mg/kg Plus Azacitidine | 6 | 51 | |
| other | Urinary tract infection | Infections and infestations | Cusatuzumab 10 mg/kg Plus Azacitdine | 5 | 51 | |
| other | Urinary tract infection | Infections and infestations | Cusatuzumab 20 mg/kg Plus Azacitidine | 3 | 51 | |
| other | Oral herpes | Infections and infestations | Cusatuzumab 10 mg/kg Plus Azacitdine | 3 | 51 | |
| other | Oral herpes | Infections and infestations | Cusatuzumab 20 mg/kg Plus Azacitidine | 3 | 51 |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04023526/events